These data indicated that siTGF-β1@ILP has better selectivity and apparent growth inhibition effects on tumors, and siRNA embedded in siTGF-β1@ILP can achieve enhanced tumor inhibition and provide improved therapeutic effects, indicating that siTGF-β1@ILP may be a promising drug delivery system for NSCLC treatment. Here, XIAP is linked to non-small cell lung carcinoma.